additional information regarding our business and product candidates is included in part i. item 1. , “ business , ” of this annual report on form 10-k. since our inception , we have devoted substantially all of our efforts to identifying and in-licensing our product candidates , organizing and staffing our company , raising capital , preparing for and advancing the clinical development of our product candidates and preparing for potential future regulatory approvals and commercialization of relugolix combination tablet and relugolix monotherapy tablet . on december 27 , 2019 , sumitovant biopharma ltd. ( “ sumitovant ” ) , a subsidiary of sumitomo dainippon pharma co. , ltd. ( “ sumitomo dainippon pharma ” ) , became our majority shareholder and a related party after acquiring approximately 50.2 % of our common shares outstanding on december 27 , 2019 . these common shares were acquired from our former majority shareholder , roivant sciences ltd. ( “ roivant , ” “ rsl , ” or “ former majority shareholder ” ) at the closing of a transaction between roivant and sumitomo dainippon pharma . as of march 31 , 2020 , sumitovant directly , and sumitomo dainippon pharma indirectly , own approximately 52.1 % of our outstanding common shares . as a result of the transfer of these common shares , roivant no longer beneficially owns any of our common shares . fiscal year ended march 31 , 2020 and recent clinical and business highlights the following summarizes our fiscal year ended march 31 , 2020 and recent clinical and business highlights . additional information regarding our relugolix and mvt-602 clinical programs is included in part i. item 1. , “ business , ” of this annual report on form 10-k. relugolix clinical programs phase 3 program for the treatment of advanced prostate cancer ( hero ) ◦ on april 21 , 2020 , we announced the submission of an nda to the fda for once-daily , oral relugolix monotherapy tablet ( 120 mg ) for the treatment of men with advanced prostate cancer . the nda submission was supported by efficacy and safety data from the phase 3 hero study , a randomized pivotal study comparing relugolix monotherapy versus leuprolide acetate . in the hero study , relugolix monotherapy met the primary efficacy endpoint with 96.7 % of men achieving sustained testosterone suppression to castrate levels ( < 50 ng/dl ) through 48 weeks , and all tested key secondary endpoints , while demonstrating 54 % fewer major adverse cardiovascular events as compared with leuprolide injections administered every 3 months . ◦ we enrolled 434 men with metastatic prostate cancer in the hero study , comprising 295 men from the original hero study and an additional cohort of 139 men that completed enrollment in july 2019. we filed an amendment to the hero study protocol to enroll 139 additional men with metastatic prostate cancer and to add the secondary objective of demonstrating that relugolix can delay the time to progression to the lethal state of the disease , castration-resistant prostate cancer , as compared to leuprolide . we currently expect to report additional data from the hero study measuring castration resistance-free survival in approximately 430 men with metastatic prostate cancer in the third quarter of calendar year 2020 . ◦ new efficacy and cardiovascular safety data from our hero study will be presented in an oral presentation at the american society of clinical oncology virtual scientific program on may 29 , 2020. phase 3 program for the treatment of heavy menstrual bleeding associated with uterine fibroids ( liberty ) ◦ on may 14 , 2019 , we announced that liberty 1 , the first of two replicate phase 3 studies evaluating once-daily relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids , met its primary efficacy endpoint and six key secondary endpoints . in the primary endpoint analysis , 73.4 % of women receiving once-daily oral relugolix combination therapy achieved the responder criteria compared with 18.9 % of women receiving placebo ( p < 0.0001 ) . the 24-week study achieved six key secondary endpoints with statistical significance compared to placebo , including mean change in menstrual blood loss from baseline to week 24 , reduction 58 in pain in women with pain at baseline , improvement in quality of life , amenorrhea ( defined as no or negligible blood loss ) , improvement in anemia in those women with anemia at baseline , and reduction in uterine volume . the seventh key secondary endpoint , reduction in uterine fibroid volume , did not achieve statistical significance . ◦ on july 23 , 2019 , we announced that liberty 2 , the second of two replicate phase 3 studies evaluating once-daily relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids , met its primary efficacy endpoint and six key secondary endpoints . in the primary endpoint analysis , 71.2 % of women receiving once-daily oral relugolix combination therapy achieved the responder criteria compared with 14.7 % of women receiving placebo ( p < 0.0001 ) . the 24-week study achieved the same six key secondary endpoints with statistical significance compared to placebo as those in liberty 1 including mean change in menstrual blood loss from baseline to week 24 , reduction in pain in women with pain at baseline , improvement in quality of life , amenorrhea ( defined as no or negligible blood loss ) , improvement in anemia in those women with anemia at baseline , and reduction in uterine volume . the seventh key secondary endpoint , reduction in uterine fibroid volume , did not achieve statistical significance . story_separator_special_tag in particular , we expect to incur increased costs associated with establishing sales , marketing , and commercialization functions in advance of potential regulatory approvals and commercialization of our product candidates . if relugolix combination tablet , relugolix monotherapy tablet , or mvt-602 obtains regulatory approval for marketing , we expect sales , marketing , and commercialization costs to be significant . interest expense interest expense consists of interest expense related to our previously outstanding debt with hercules and novaquest as well as the associated non-cash amortization of debt discounts and issuance costs . interest expense ( related party ) interest expense ( related party ) consists of interest expense pursuant to the sumitomo dainippon pharma loan agreement , which bears interest at a rate per annum equal to 3-month libor plus a margin of 3 % payable on the last day of each calendar quarter . the anticipated increases in our outstanding debt under the sumitomo dainippon pharma loan agreement will result in an increase in interest expense ( related party ) in future periods . interest income interest income consists primarily of interest earned on corporate bonds and money market funds and the accretion of discounts to maturity for commercial paper . loss on extinguishment of debt loss on extinguishment of debt represents the difference between the carrying amount of our previously outstanding debt with hercules and novaquest and the amounts we paid to retire the outstanding debt obligations on december 31 , 2019 . 62 results of operations the following table summarizes our results of operations for the years ended march 31 , 2020 and 2019 , respectively ( in thousands ) : replace_table_token_0_th research and development expenses for the years ended march 31 , 2020 and 2019 , our r & d expenses consisted of the following ( in thousands ) : replace_table_token_1_th r & d expenses decreased by $ 30.0 million , to $ 192.6 million , for the year ended march 31 , 2020 compared to $ 222.6 million for the year ended march 31 , 2019 . r & d expenses in both periods primarily include expenses related to our phase 3 clinical programs , manufacturing expenses , as well as personnel-related expenses for employees engaged in r & d activities . r & d expenses for the year ended march 31 , 2019 reflected a ramp up in relugolix phase 3 study costs primarily related to study enrollment , whereas r & d expenses for the year ended march 31 , 2020 reflect declining relugolix phase 3 study costs as certain studies are in the process of winding down . the decrease in relugolix phase 3 study costs of approximately $ 50.9 million were partially offset by increases in other r & d expenses related predominantly to regulatory activities in connection with regulatory submissions for relugolix combination tablet and relugolix monotherapy tablet in multiple indications and jurisdictions and the build out of our medical affairs organization in connection with preparations for our anticipated commercial launches , as well as increases in personnel expenses , share-based compensation expense , and other r & d expenses . r & d expenses for the year ended march 31 , 2020 consisted primarily of program-specific costs comprised of cro , drug supply and other study , regulatory , and manufacturing related costs of $ 133.4 million , personnel expenses of $ 32.7 million , share-based compensation expense of $ 14.5 million , and other r & d costs of $ 11.9 million , which primarily includes contractors , consultants , and information technology costs . share-based compensation expense includes $ 1.8 million related to the accelerated vesting of certain equity awards as a result of a change in control in myovant in connection with the closing of the transaction between roivant and sumitomo dainippon pharma . 63 r & d expenses for the year ended march 31 , 2019 consisted primarily of cro , clinical drug supply and other study and manufacturing related costs of $ 186.4 million , personnel-related expenses of $ 23.2 million , share-based compensation expense of $ 7.2 million , and costs billed to us under the then existing services agreements with roivant of $ 2.3 million , including unallocated personnel expenses and third-party pass-through costs associated with our clinical and other research programs . general and administrative expenses g & a expenses increased by $ 40.1 million to $ 82.3 million for the year ended march 31 , 2020 compared to $ 42.2 million for the year ended march 31 , 2019 , primarily due to increases in expenses related to commercial operations activities in advance of potential future regulatory approvals of relugolix combination tablet and relugolix monotherapy tablet , personnel-related expenses , and share-based compensation expenses , as well as professional service fees , other general overhead , administrative , and information technology expenses to support our headcount growth and expanding operations and the assumption of activities previously provided by roivant , partially offset by a reduction of costs billed to us under the then existing services agreements with roivant as a result of our assumption of these activities by our own personnel and other third party service providers . g & a expenses for the year ended march 31 , 2020 include certain one-off increases as a result of the change in control in myovant in connection with the closing of the transaction between roivant and sumitomo dainippon pharma , namely $ 10.2 million in share-based compensation expense related to the accelerated vesting of certain equity awards as well as a $ 3.6 million capital tax accrual . for the year ended march 31 , 2020 , g & a expenses consisted primarily of share-based compensation expense of $ 25.7 million , personnel-related expenses of $ 19.1 million , commercial operations expenses of $ 12.7 million , general overhead , administrative and information technology expenses of $ 11.9 million , professional service fees of $ 6.0 million , capital

cash flows the following table sets forth a summary of our cash flows ( in thousands ) : replace_table_token_2_th operating activities for the year ended march 31 , 2020 we used $ 221.2 million in operating activities primarily due to our ongoing clinical studies , activities related to our preparation for potential regulatory approvals and commercialization of relugolix combination tablet and 66 relugolix monotherapy tablet , and the expansion of our company . this was primarily attributable to a net loss for the period of $ 289.0 million and a decrease of $ 24.6 million in accrued expenses resulting primarily from a decrease in accrued r & d expenses and decreases of $ 1.1 million in interest payable and $ 2.3 million in deferred interest payable related to our previously outstanding debt which was repaid in full on december 31 , 2019. these amounts were partially offset by an increase of $ 40.0 million in current deferred revenue related to the upfront payment we received from richter on march 31 , 2020 , an increase in accounts payable of $ 4.3 million , due to timing of invoice payments , and an increase in other liabilities of $ 3.6 million , due to a capital tax accrual as a result of the change in control in myovant , along with non-cash items including $ 40.3 million of share-based compensation expense as a result of an increase in headcount ( which also includes $ 12.0 million related to the accelerated vesting of certain equity awards as a result of the change in control in myovant in connection with the closing of the transaction between roivant and sumitomo dainippon pharma ) , $ 3.3 million of total depreciation and amortization expense , and a $ 4.9 million loss on extinguishment of debt associated with the write-off of unamortized debt issuance costs and debt discounts , prepayment penalties and early redemption fees in connection with the repayment of outstanding obligations to novaquest and hercules on december 31 , 2019 .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows the following table sets forth a summary of our cash flows ( in thousands ) : replace_table_token_2_th operating activities for the year ended march 31 , 2020 we used $ 221.2 million in operating activities primarily due to our ongoing clinical studies , activities related to our preparation for potential regulatory approvals and commercialization of relugolix combination tablet and 66 relugolix monotherapy tablet , and the expansion of our company . this was primarily attributable to a net loss for the period of $ 289.0 million and a decrease of $ 24.6 million in accrued expenses resulting primarily from a decrease in accrued r & d expenses and decreases of $ 1.1 million in interest payable and $ 2.3 million in deferred interest payable related to our previously outstanding debt which was repaid in full on december 31 , 2019. these amounts were partially offset by an increase of $ 40.0 million in current deferred revenue related to the upfront payment we received from richter on march 31 , 2020 , an increase in accounts payable of $ 4.3 million , due to timing of invoice payments , and an increase in other liabilities of $ 3.6 million , due to a capital tax accrual as a result of the change in control in myovant , along with non-cash items including $ 40.3 million of share-based compensation expense as a result of an increase in headcount ( which also includes $ 12.0 million related to the accelerated vesting of certain equity awards as a result of the change in control in myovant in connection with the closing of the transaction between roivant and sumitomo dainippon pharma ) , $ 3.3 million of total depreciation and amortization expense , and a $ 4.9 million loss on extinguishment of debt associated with the write-off of unamortized debt issuance costs and debt discounts , prepayment penalties and early redemption fees in connection with the repayment of outstanding obligations to novaquest and hercules on december 31 , 2019 .
```    
 Suspicious Activity Report : additional information regarding our business and product candidates is included in part i. item 1. , “ business , ” of this annual report on form 10-k. since our inception , we have devoted substantially all of our efforts to identifying and in-licensing our product candidates , organizing and staffing our company , raising capital , preparing for and advancing the clinical development of our product candidates and preparing for potential future regulatory approvals and commercialization of relugolix combination tablet and relugolix monotherapy tablet . on december 27 , 2019 , sumitovant biopharma ltd. ( “ sumitovant ” ) , a subsidiary of sumitomo dainippon pharma co. , ltd. ( “ sumitomo dainippon pharma ” ) , became our majority shareholder and a related party after acquiring approximately 50.2 % of our common shares outstanding on december 27 , 2019 . these common shares were acquired from our former majority shareholder , roivant sciences ltd. ( “ roivant , ” “ rsl , ” or “ former majority shareholder ” ) at the closing of a transaction between roivant and sumitomo dainippon pharma . as of march 31 , 2020 , sumitovant directly , and sumitomo dainippon pharma indirectly , own approximately 52.1 % of our outstanding common shares . as a result of the transfer of these common shares , roivant no longer beneficially owns any of our common shares . fiscal year ended march 31 , 2020 and recent clinical and business highlights the following summarizes our fiscal year ended march 31 , 2020 and recent clinical and business highlights . additional information regarding our relugolix and mvt-602 clinical programs is included in part i. item 1. , “ business , ” of this annual report on form 10-k. relugolix clinical programs phase 3 program for the treatment of advanced prostate cancer ( hero ) ◦ on april 21 , 2020 , we announced the submission of an nda to the fda for once-daily , oral relugolix monotherapy tablet ( 120 mg ) for the treatment of men with advanced prostate cancer . the nda submission was supported by efficacy and safety data from the phase 3 hero study , a randomized pivotal study comparing relugolix monotherapy versus leuprolide acetate . in the hero study , relugolix monotherapy met the primary efficacy endpoint with 96.7 % of men achieving sustained testosterone suppression to castrate levels ( < 50 ng/dl ) through 48 weeks , and all tested key secondary endpoints , while demonstrating 54 % fewer major adverse cardiovascular events as compared with leuprolide injections administered every 3 months . ◦ we enrolled 434 men with metastatic prostate cancer in the hero study , comprising 295 men from the original hero study and an additional cohort of 139 men that completed enrollment in july 2019. we filed an amendment to the hero study protocol to enroll 139 additional men with metastatic prostate cancer and to add the secondary objective of demonstrating that relugolix can delay the time to progression to the lethal state of the disease , castration-resistant prostate cancer , as compared to leuprolide . we currently expect to report additional data from the hero study measuring castration resistance-free survival in approximately 430 men with metastatic prostate cancer in the third quarter of calendar year 2020 . ◦ new efficacy and cardiovascular safety data from our hero study will be presented in an oral presentation at the american society of clinical oncology virtual scientific program on may 29 , 2020. phase 3 program for the treatment of heavy menstrual bleeding associated with uterine fibroids ( liberty ) ◦ on may 14 , 2019 , we announced that liberty 1 , the first of two replicate phase 3 studies evaluating once-daily relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids , met its primary efficacy endpoint and six key secondary endpoints . in the primary endpoint analysis , 73.4 % of women receiving once-daily oral relugolix combination therapy achieved the responder criteria compared with 18.9 % of women receiving placebo ( p < 0.0001 ) . the 24-week study achieved six key secondary endpoints with statistical significance compared to placebo , including mean change in menstrual blood loss from baseline to week 24 , reduction 58 in pain in women with pain at baseline , improvement in quality of life , amenorrhea ( defined as no or negligible blood loss ) , improvement in anemia in those women with anemia at baseline , and reduction in uterine volume . the seventh key secondary endpoint , reduction in uterine fibroid volume , did not achieve statistical significance . ◦ on july 23 , 2019 , we announced that liberty 2 , the second of two replicate phase 3 studies evaluating once-daily relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids , met its primary efficacy endpoint and six key secondary endpoints . in the primary endpoint analysis , 71.2 % of women receiving once-daily oral relugolix combination therapy achieved the responder criteria compared with 14.7 % of women receiving placebo ( p < 0.0001 ) . the 24-week study achieved the same six key secondary endpoints with statistical significance compared to placebo as those in liberty 1 including mean change in menstrual blood loss from baseline to week 24 , reduction in pain in women with pain at baseline , improvement in quality of life , amenorrhea ( defined as no or negligible blood loss ) , improvement in anemia in those women with anemia at baseline , and reduction in uterine volume . the seventh key secondary endpoint , reduction in uterine fibroid volume , did not achieve statistical significance . story_separator_special_tag in particular , we expect to incur increased costs associated with establishing sales , marketing , and commercialization functions in advance of potential regulatory approvals and commercialization of our product candidates . if relugolix combination tablet , relugolix monotherapy tablet , or mvt-602 obtains regulatory approval for marketing , we expect sales , marketing , and commercialization costs to be significant . interest expense interest expense consists of interest expense related to our previously outstanding debt with hercules and novaquest as well as the associated non-cash amortization of debt discounts and issuance costs . interest expense ( related party ) interest expense ( related party ) consists of interest expense pursuant to the sumitomo dainippon pharma loan agreement , which bears interest at a rate per annum equal to 3-month libor plus a margin of 3 % payable on the last day of each calendar quarter . the anticipated increases in our outstanding debt under the sumitomo dainippon pharma loan agreement will result in an increase in interest expense ( related party ) in future periods . interest income interest income consists primarily of interest earned on corporate bonds and money market funds and the accretion of discounts to maturity for commercial paper . loss on extinguishment of debt loss on extinguishment of debt represents the difference between the carrying amount of our previously outstanding debt with hercules and novaquest and the amounts we paid to retire the outstanding debt obligations on december 31 , 2019 . 62 results of operations the following table summarizes our results of operations for the years ended march 31 , 2020 and 2019 , respectively ( in thousands ) : replace_table_token_0_th research and development expenses for the years ended march 31 , 2020 and 2019 , our r & d expenses consisted of the following ( in thousands ) : replace_table_token_1_th r & d expenses decreased by $ 30.0 million , to $ 192.6 million , for the year ended march 31 , 2020 compared to $ 222.6 million for the year ended march 31 , 2019 . r & d expenses in both periods primarily include expenses related to our phase 3 clinical programs , manufacturing expenses , as well as personnel-related expenses for employees engaged in r & d activities . r & d expenses for the year ended march 31 , 2019 reflected a ramp up in relugolix phase 3 study costs primarily related to study enrollment , whereas r & d expenses for the year ended march 31 , 2020 reflect declining relugolix phase 3 study costs as certain studies are in the process of winding down . the decrease in relugolix phase 3 study costs of approximately $ 50.9 million were partially offset by increases in other r & d expenses related predominantly to regulatory activities in connection with regulatory submissions for relugolix combination tablet and relugolix monotherapy tablet in multiple indications and jurisdictions and the build out of our medical affairs organization in connection with preparations for our anticipated commercial launches , as well as increases in personnel expenses , share-based compensation expense , and other r & d expenses . r & d expenses for the year ended march 31 , 2020 consisted primarily of program-specific costs comprised of cro , drug supply and other study , regulatory , and manufacturing related costs of $ 133.4 million , personnel expenses of $ 32.7 million , share-based compensation expense of $ 14.5 million , and other r & d costs of $ 11.9 million , which primarily includes contractors , consultants , and information technology costs . share-based compensation expense includes $ 1.8 million related to the accelerated vesting of certain equity awards as a result of a change in control in myovant in connection with the closing of the transaction between roivant and sumitomo dainippon pharma . 63 r & d expenses for the year ended march 31 , 2019 consisted primarily of cro , clinical drug supply and other study and manufacturing related costs of $ 186.4 million , personnel-related expenses of $ 23.2 million , share-based compensation expense of $ 7.2 million , and costs billed to us under the then existing services agreements with roivant of $ 2.3 million , including unallocated personnel expenses and third-party pass-through costs associated with our clinical and other research programs . general and administrative expenses g & a expenses increased by $ 40.1 million to $ 82.3 million for the year ended march 31 , 2020 compared to $ 42.2 million for the year ended march 31 , 2019 , primarily due to increases in expenses related to commercial operations activities in advance of potential future regulatory approvals of relugolix combination tablet and relugolix monotherapy tablet , personnel-related expenses , and share-based compensation expenses , as well as professional service fees , other general overhead , administrative , and information technology expenses to support our headcount growth and expanding operations and the assumption of activities previously provided by roivant , partially offset by a reduction of costs billed to us under the then existing services agreements with roivant as a result of our assumption of these activities by our own personnel and other third party service providers . g & a expenses for the year ended march 31 , 2020 include certain one-off increases as a result of the change in control in myovant in connection with the closing of the transaction between roivant and sumitomo dainippon pharma , namely $ 10.2 million in share-based compensation expense related to the accelerated vesting of certain equity awards as well as a $ 3.6 million capital tax accrual . for the year ended march 31 , 2020 , g & a expenses consisted primarily of share-based compensation expense of $ 25.7 million , personnel-related expenses of $ 19.1 million , commercial operations expenses of $ 12.7 million , general overhead , administrative and information technology expenses of $ 11.9 million , professional service fees of $ 6.0 million , capital

